|
Cytos to Secure up to CHF 37M to Advance Phase II Asthma Immunotherapy
Genetic Engineering News The funds will enable Cytos to conduct a global multicenter Phase IIb trial with its lead product CYT003-QbG10 in patients suffering from allergic asthma as well as to advance the rest of its pipeline. This transaction completes the financial … Cytos revives lead program in $40M financing deal with Amgen, venBio |
View full post on asthma – Google News